688315.SH
诺禾致源
SSE · Healthcare · Biotechnology · CN
CNY 16.93
+6.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3B | 2.2B | 2.1B | 2.0B | 1.9B |
| Cost of Revenue | 1.3B | 1.3B | 1.2B | 1.1B | 1.1B |
| Gross Profit | 974.4M | 939.8M | 923.6M | 855.6M | 852.7M |
| Operating Expenses | |||||
| R&D Expense | 166.5M | 159.9M | 131.4M | 124.2M | 125.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 145.3M | 145.3M | 158.3M | 177.6M | 172.2M |
| Selling & Marketing Expense | 461.5M | 443.6M | 406.0M | 379.1M | 331.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 776.2M | 741.2M | 694.7M | 670.6M | 626.2M |
| Cost and Expenses | 2.1B | 2.0B | 1.9B | 1.8B | 1.7B |
| Operating Income (EBIT) | 192.8M | 193.5M | 234.0M | 214.9M | 212.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 192.3M | 192.9M | 224.7M | 212.6M | 208.6M |
| Income Tax Expense | 24.9M | 21.4M | 20.9M | 29.4M | 27.0M |
| Bottom Line | |||||
| Net Income | 162.5M | 166.9M | 196.8M | 178.1M | 177.2M |
| Earnings from Cont. Ops | 167.5M | 171.5M | 203.8M | 183.2M | 181.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 162.5M | 166.9M | 196.8M | 178.1M | 177.2M |
| Per Share | |||||
| Basic EPS | CN¥0.40 | CN¥0.41 | CN¥0.48 | CN¥0.44 | CN¥0.44 |
| Diluted EPS | CN¥0.40 | CN¥0.41 | CN¥0.48 | CN¥0.44 | CN¥0.44 |
| Revenue Per Share | CN¥5.38 | CN¥5.43 | CN¥5.15 | CN¥4.95 | CN¥4.78 |
| Shares | |||||
| Basic Shares Outstanding | 420.7M | 407.2M | 410.0M | 404.7M | 402.8M |
| Diluted Shares Outstanding | 420.7M | 407.2M | 410.0M | 404.7M | 402.8M |
| Profitability Metrics | |||||
| EBITDA | — | 325.8M | 376.1M | 347.6M | 330.2M |
| D&A | — | 132.3M | 142.1M | 132.7M | 117.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026